M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth

FomoAnxiety · 2026-03-24T04:42:38+00:00

Gilead Sciences has agreed to acquire Ouro Medicines for over $2 billion to expand its immunology portfolio. The deal includes $1.68 billion upfront and potential milestone payments of $500 million, reflecting Gilead's strategy to diversify in the immune disorder treatment market.

FomoAnxiety

2026-03-24 04:42:38

Abstract generation in progress

Gilead Sciences GILD +0.09% ▲ has agreed to acquire privately held biotech firm Ouro Medicines in a deal valued at over $2 billion to expand into immunology. The transaction includes $1.68 billion in upfront cash, with up to an additional $500 million tied to milestone-based payments. Notably, the acquisition highlights Gilead’s strategy to diversify beyond its core portfolio and capitalize on the fast-growing market for immune disorder treatments.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

For context, Gilead Sciences is known for its treatments in HIV, antiviral therapies, and oncology, with a growing focus on immunology. Meanwhile, Ouro Medicines develops innovative therapies for immune-related diseases, with a focus on next-generation immunology treatments.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes